Provider Briefing: Cortisporin-Tc Availability in 2026

If your patients are reporting difficulty filling prescriptions for Cortisporin-Tc (colistin sulfate/neomycin sulfate/thonzonium bromide/hydrocortisone acetate otic suspension), you're hearing a consistent theme. While Cortisporin-Tc is not on the FDA's formal drug shortage list, real-world access barriers — including limited pharmacy stocking, brand-only pricing, and restrictive formulary placement — create functional shortages that affect patient care.

This briefing covers the current state of Cortisporin-Tc availability, what's driving the access challenges, prescribing alternatives, and tools to help your patients locate the medication when it's specifically indicated.

Timeline: How We Got Here

The Cortisporin product line has undergone significant ownership and availability changes over the past decade:

• 2014: Par Pharmaceutical acquired JHP Pharmaceuticals, inheriting the Cortisporin-Tc product line
• 2015: Endo International acquired Par Pharmaceutical, consolidating Cortisporin-Tc under Endo Pharmaceuticals (Endo USA, Inc.)
• 2018: King Pharmaceuticals (a former Cortisporin brand holder) discontinued Cortisporin Otic Suspension (neomycin/polymyxin B/hydrocortisone). The FDA confirmed this was not for safety or efficacy reasons.
• 2019: Endo relaunched Cortisporin-Tc Otic Suspension with updated labeling (NDC 63481-529-10)
• 2020–2026: No formal manufacturing shortage, but persistent pharmacy-level availability gaps due to brand-only status and low stocking rates

Prescribing Implications

Formulary and Coverage Challenges

Cortisporin-Tc faces significant insurance coverage barriers:

• No generic exists for this specific four-ingredient combination, keeping it at brand-name pricing ($234–$350 per 10 mL bottle)
• Most commercial and Medicare Part D formularies either exclude Cortisporin-Tc or place it on Tier 3/non-preferred brand tiers with copays of $50–$100+
• Step therapy requirements are common — payers typically require trial and failure of generic ofloxacin otic or neomycin/polymyxin B/hydrocortisone first
• Prior authorization may be required, adding administrative burden to the prescribing workflow

When Cortisporin-Tc Is Specifically Indicated

While many ear infections can be adequately treated with alternative agents, there are clinical scenarios where Cortisporin-Tc may be specifically preferred:

• Infections in mastoidectomy and fenestration cavities where the unique colistin/neomycin combination and thonzonium penetration agent offer a clinical advantage
• Cases where polymyxin B (in standard Cortisporin Otic) has not been effective and the colistin-based formulation is warranted
• Patient-specific factors such as allergy profiles that rule out fluoroquinolone alternatives

For routine acute otitis externa in an otherwise healthy patient with an intact tympanic membrane, clinical guidelines support first-line use of fluoroquinolone otic drops (ofloxacin, ciprofloxacin-based agents), making Cortisporin-Tc a second- or third-line choice in most algorithms.

Current Availability Picture

Cortisporin-Tc remains in active production by Endo Pharmaceuticals. The availability challenge is primarily at the retail pharmacy stocking level:

• Large chain pharmacies (CVS, Walgreens, Rite Aid) frequently do not stock Cortisporin-Tc due to low turnover and high inventory cost
• Independent pharmacies with access to multiple wholesalers may have better success sourcing it
• Hospital outpatient pharmacies and those affiliated with ENT practices are more likely to carry it
• Special orders from wholesalers typically take 1–2 business days when the product is available at the distribution level

Cost and Patient Access

The financial burden on patients is a significant clinical consideration:

• Cash price: $234–$350 for a 10 mL bottle
• Discount card pricing: GoodRx Gold may bring the price to ~$224; SingleCare and other programs offer modest reductions
• No manufacturer copay card or savings program is currently available from Endo Pharmaceuticals
• No dedicated patient assistance program (PAP) exists for Cortisporin-Tc
• General PAP resources like NeedyMeds and RxAssist may provide alternative guidance for financially distressed patients

Tools and Resources for Providers

Medfinder for Providers

Medfinder for Providers enables your practice to check pharmacy-level availability for hard-to-find medications like Cortisporin-Tc. Rather than directing patients to call multiple pharmacies, you can use the platform to identify stocked locations before the patient leaves your office — reducing time-to-fill and improving adherence.

Prior Authorization Support

When Cortisporin-Tc is clinically indicated and a PA is required, document:

• The specific indication (e.g., mastoidectomy cavity infection)
• Why alternatives are inadequate (e.g., treatment failure with generic agents, allergy to fluoroquinolones)
• The expected treatment duration (typically 10 days or less)

Helping Patients Find It

If you've determined that Cortisporin-Tc is the right medication for your patient, our guide for providers on how to help patients find Cortisporin-Tc in stock offers a practical workflow for your office.

Alternative Agents: Quick Reference

When Cortisporin-Tc is unavailable or cost-prohibitive, the following agents may be appropriate substitutes depending on clinical context:

• Ofloxacin otic 0.3% — First-line for most otitis externa; generic, $10–$30; safe with perforated TM
• Ciprofloxacin/dexamethasone otic (generic Ciprodex) — Antibiotic + steroid; $50–$100 generic; safe with perforated TM and tubes
• Neomycin/polymyxin B/hydrocortisone otic (generic Cortisporin Otic) — Closest formulation match; $15–$40; contraindicated with perforated TM
• Ciprofloxacin/hydrocortisone otic (Cipro HC) — Antibiotic + steroid; brand-only ~$300+; contraindicated with perforated TM

For patient-facing information on alternatives, direct patients to our article on alternatives to Cortisporin-Tc.

Looking Ahead

As of early 2026, there are no publicly known ANDA filings for a generic version of Cortisporin-Tc. The market dynamics — a relatively small patient population, complex four-ingredient formulation, and the availability of multiple otic alternatives — may discourage generic manufacturers from entering this space in the near term.

Providers should continue to assess whether Cortisporin-Tc is specifically necessary for each patient or whether more accessible alternatives can achieve equivalent clinical outcomes. When it is needed, tools like Medfinder for Providers can help bridge the gap between prescription and fill.

Final Thoughts

Cortisporin-Tc occupies an unusual position in the otic antibiotic landscape — still manufactured, not formally in shortage, yet genuinely difficult for patients to access. Understanding the market dynamics, having a clear alternative algorithm, and leveraging availability tools can help you serve patients effectively even when their first-choice medication isn't readily available.

For additional clinical information, see our articles on Cortisporin-Tc mechanism of action and drug interactions.